Relapsed and/or refractory AML or MDS research hub

AdaptNK –Cell Therapy for High-risk Myeloid Disease

This study is testing a new cell therapy called AdaptNK for adults with certain blood cancers (AML or MDS) that haven't responded to usual treatments. It's an early-stage trial looking at whether the treatment is safe and if it helps.